Your medical cannabis journey simplified: find partnered dispensaries, explore pricing options, earn rewards, and get answers to FAQs, all in one spot.
December 15, 2020 11:30 am ETEstimated Read Time: 5 Minutes
The United Nations Commission on Narcotic Drugs (CND) has accepted the World Health Organization’s (WHO) recommendation to remove cannabis from the current schedule IV listing of 1961. This historic decision comes long-overdue but well-accepted. This decision can have sweeping implications for the worldwide medical cannabis industry. One of the most important implications may be that cannabis research can be conducted on a larger scale and more in-depth in order to get a better understanding of the plant and its medical benefits. The decision was made in Vienna and was only accepted due to a slim majority of votes in favor of cannabis. There were a total of 27 votes in favor of removing cannabis from the Schedule IV drug listing, with 25 against and 1 abstention.
Who Are the CND and WHO?
The CND, or United Nations Commission on Narcotic Drugs, is the official and main drug policy-making body of the United Nations, which includes around 193 members such as Australia, Brazil, the United Kingdom, and even the United States. The CND was established by the Economic and Social Council (ECOSOC) in 1946 in order to supervise international drug control. The mandate of the CND is to “review and analyze the global drug situation, considering supply and demand reduction” and it “takes action through resolutions and decisions”.
WHO, or the World Health Organization, works with the United Nations in order to combat diseases. It was established back in 1948. The primary role of the World Health Organization is to “direct and coordinate international health within the United Nations”. WHO works with health systems including life-course, non-communicable and communicable disease, preparedness, surveillance, and response as well as corporate services.
The Schedule IV Drug Listing Explained
The Single Convention on Narcotic Drugs of 1961 is an international treaty that prohibits the production and supply of specific drugs. The single convention listed cannabis as a Schedule IV (4) which is a category of drugs that are considered as having dangerous properties such as addiction which leads to serious health complications. When looking at the list of drugs on this schedule, one will see drugs like heroin and opiates. However, unlike those drugs, cannabis is far less dangerous with little to no chance of an overdose leading to death. This scheduling is not the same as the U.S Controlled Substance Act, which has schedules ranging from I to V (1-5). In the U.S Controlled Substance Act, cannabis is a Schedule I drug where it joins the ranks of substances with a high potential for abuse and no medical value such as heroin, psilocybin, LSD, methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Apply For Your Medical Marijuana Card Today
Veriheal has satisfied hundreds of thousands of patients nationwide
Get approved or your money back
Appointments available on-demand
Customer support available 24/7
Removing Cannabis From Schedule IV
When the CND accepted WHO’s recommendation to remove cannabis from the 1961 schedule IV, they acknowledged the medical utility of cannabis (finally!). The drugs and democracy program director of the Netherlands-based Transnational Institute recently noted in an interview with MJBizDaily that, “the medical cannabis wave has accelerated in recent years already, but this will give it another boost”. The votes in favor of this decision will hopefully encourage other countries to re-evaluate how cannabis is currently classified in their respective lists of narcotic drugs. However, the convention made it clear that citizens can NOT expect a sudden relaxation of international controls that govern medical cannabis.
The CND decided to accept the recommendation based on the fact that cannabis does not meet the risk profile associated with the other drugs on the list. WHO actually prepared a package of 6 recommendations for cannabis but only 1 of those were accepted- which is the decision to remove cannabis from the schedule IV listing called “recommendation 5.1”. Recommendations 5.2-5.5 received a majority of the votes against them.
What Are the Implications?
Kenzi Riboulet-Zimouli of the CND Monitor also stated in an interview with MJBizDaily that ”decades of efforts have been necessary to remove cannabis from Schedule IV, with implications that will slowly but surely be seen over the next decades”. However, we can predict that the implications of this decision will only benefit. Benefits that include the following:
Boosts medical cannabis legalization efforts
May lead to national descheduling in UN countries
Removing obstacles to use cannabis for medical and research purposes
Currently, medical cannabis legalization efforts, as well as research of cannabis, has been severely hindered by the harsh scheduling of cannabis on drug lists. The implications of this decision may only reveal themselves in the coming years but the decision is already one major advancement towards supporting medical cannabis legalization efforts. As those efforts are supported and boosted by authorities such as CND and WHO, countries will be encouraged to reconsider the classification of cannabis- which means to consider descheduling. By removing cannabis from the scheduling and moving towards its legalization, patients will be able to access medical cannabis with more ease and researchers will be able to make use of the botanical substances, as opposed to synthetic versions, in order to get a better understanding of the plant, how it interacts with body as well as identifying certain benefits from its consumption.
This is a major win for the cannabis community as more research is conducted in order to further eliminate controversy around its use, effectiveness, and risks. Medical cannabis has already proven, despite restricted research, that it is more effective and beneficial with lower risks compared to man-made cannabinoids and pharmaceutical medication.
Chane Leigh, aka The Bud Fairy, is a South African cannabis advocate and enthusiast with a firey personality and a thirst for travel. She loves to educate people and to question the norms.
Blunts: What are they exactly, and how do they affect your body? If you’re interested in smoking blunts—or already smoke them—this guide is for you. We’ll cover everything you need to know about this popular cannabis intake method, including how they’re made, how they differ from spliffs and joints, risks of use, and alternative intake…
“Stoned,” “high,” “tripping,” and “baked,” are all terms engrained in the cannabis community. These metaphorical descriptions contribute to how we perceive, interpret, and learn from the experiences produced by cannabis consumption. Cannabis experiences, of course, are unique and highly variable. Specific plant strains, the presence of other cannabinoids, different delivery methods, and a user’s individual…
Thanks to the growing wave of legalization, more consumers than ever can grow their own cannabis right at home. Growing essentials that used to be secretive are now bought and sold freely. This includes items, like grow tents, nutrients, LED lighting, HPS lighting, ventilation, and more. Keeping all these items straight is hard enough, but…
Skin diseases plague millions of individuals, inflicting both physical discomforts in addition to mental and social stress. Thankfully, there is no shortage of skin treatment options available on the market. That said, this established market may soon be in for a major shake-up if recent cannabis research is any indication. Traditionally, cannabis research focused on studying…
As more states move toward legalization, accurately detecting impaired driving is of the utmost importance. Field Sobriety Tests (FSTs) have long been the go-to method for law enforcement to assess driver impairment caused by substances like alcohol. However, a recent 2023 study published in JAMA Psychiatry raises serious questions about the accuracy of these tests…
We use our own as well as third party cookies to improve your site experience and the services we make available. You can learn more about our use of cookies in our Privacy Policy.
Content Disclamer
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.